Next |
home / stock / scps / scps message board
Subject | By | Source | When |
---|---|---|---|
$SCPS: effective Dec. 19,2022 $SCPS delisted from the | Renee | investorshub | 12/16/2022 10:14:10 PM |
znewcar1: $SCPS 44% v31,4M c.3401 f21,0M pmh..6 hod.5794 then fell | znewcar1 | investorshangout | 12/16/2022 4:06:11 AM |
Wonder why the spike today? | RAlbert | investorshub | 12/15/2022 1:52:19 PM |
SITC started 2 days ago November 8 and | FACT-MASTER | investorshub | 11/11/2022 4:00:42 AM |
NEWS SITC 2022 : | FACT-MASTER | investorshub | 11/10/2022 11:13:00 PM |
znewcar1: $SCPS 51% v15,9M c.372 f21,1M H.51 ML.21 | znewcar1 | investorshangout | 10/20/2022 3:24:42 AM |
Duet 01 Clinical Trial link here: | FACT-MASTER | investorshub | 10/20/2022 2:50:51 AM |
Duet BioPharma Pipeline: | FACT-MASTER | investorshub | 10/20/2022 2:49:51 AM |
Volume RIPPING! Nice close at .3720! | FACT-MASTER | investorshub | 10/20/2022 2:16:04 AM |
Bit of a heartbeat here today ! | FACT-MASTER | investorshub | 10/20/2022 2:14:12 AM |
Home page for Duet BioTherapeutics: | FACT-MASTER | investorshub | 10/19/2022 2:34:42 PM |
Interesting NEWS OUT! | FACT-MASTER | investorshub | 10/18/2022 2:50:06 PM |
Oct.7/22 8K posted here re: Nasdaq compliance | FACT-MASTER | investorshub | 10/08/2022 1:19:22 AM |
Level II TRANSLATION = we are all screwed. | FACT-MASTER | investorshub | 09/29/2022 7:32:21 PM |
Update on estimated trial start date August 1/22 | FACT-MASTER | investorshub | 09/27/2022 10:13:13 PM |
I don't think we will survive Nasdaq | FACT-MASTER | investorshub | 09/21/2022 9:18:56 PM |
That was an outright TEASE !! | FACT-MASTER | investorshub | 08/25/2022 11:23:17 PM |
Could also be further financing in the pipeline. | FACT-MASTER | investorshub | 08/25/2022 2:50:51 PM |
SUUMTH'INS UP, imo.!! | FACT-MASTER | investorshub | 08/25/2022 2:36:33 PM |
Delaware trial now scheduled for 2023! | FACT-MASTER | investorshub | 08/16/2022 12:23:13 AM |
News, Short Squeeze, Breakout and More Instantly...
Scopus BioPharma Inc. Company Name:
SCPS Stock Symbol:
NASDAQ Market:
Scopus BioPharma Inc. Website:
DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus B...
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS ”) , a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is...
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) , a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet Bi...